about
NOD-Like Receptors in Infection, Immunity, and DiseasesTo Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory TherapiesInflammasomes: mechanism of action, role in disease, and therapeuticsWound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancerGout increases risk of fracture: A nationwide population-based cohort study.Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.When less is more: primary immunodeficiency with an autoinflammatory kickInflammasomes.Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalanceIL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice.Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.Decreased expression levels of Ifi genes is associated to the increased resistance to spontaneous arthritis disease in mice deficiency of IL-1RA.Molecular Basis of Acute Cystitis Reveals Susceptibility Genes and Immunotherapeutic Targets.Suppression of NLRP3 inflammasome by γ-tocotrienol ameliorates type 2 diabetesTransient increase of interleukin-1β after prolonged febrile seizures promotes adult epileptogenesis through long-lasting upregulating endocannabinoid signaling.Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory diseaseIL-1 Receptor Signaling on Graft Parenchymal Cells Regulates Memory and De Novo Donor-Reactive CD8 T Cell Responses to Cardiac AllograftsBisphosphonate Induces Osteonecrosis of the Jaw in Diabetic Mice via NLRP3/Caspase-1-Dependent IL-1β Mechanism.Quercetin Inhibits Inflammasome Activation by Interfering with ASC Oligomerization and Prevents Interleukin-1 Mediated Mouse Vasculitis.Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS).Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability.Important differences in the diagnostic spectrum of primary immunodeficiency in adults versus children.Diagnosis of cryopyrin-associated periodic syndrome: challenges, recommendations and emerging concepts.Current knowledge on procaspase-1 variants with reduced or abrogated enzymatic activity in autoinflammatory disease.Pathogenesis of Behçet's disease: autoinflammatory features and beyond.The role of cytokine deficiencies and cytokine autoantibodies in clinical dermatology.Recurrent Fevers for the Pediatric Immunologist: It's Not All Immunodeficiency.Genetically defined autoinflammatory diseases.The NLRP3 inflammasome in kidney disease and autoimmunity.Inflammasomes and dermatology.Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation.Oxalate, inflammasome, and progression of kidney diseaseAutoinflammation and HLA-B27: Beyond Antigen Presentation.Autoinflammatory diseases: update on classification diagnosis and management.The NLRP3 Inflammasome Has a Critical Role in Peritoneal Dialysis-Related Peritonitis.Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.Lessons from characterization and treatment of the autoinflammatory syndromes.The inflammasome as a target for pain therapy.Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.
P2860
Q26775253-9CB69DFD-F6D4-4B2B-ADE0-CBAC02B1229CQ26786973-7F6E3DAE-C185-48D7-9B0A-067D3558A93EQ27001186-835FA62C-E05B-4714-97E1-05E2ED90D466Q27023599-34F68E5F-A0FA-446C-9835-920B0662711AQ33590612-082AC61A-DF2C-44E7-B69C-35B9852DFBBFQ33710807-9C62F445-EC6D-43F1-8A63-708E52AB4E05Q34420031-5C0CF6E0-1BC9-4B1C-9D0F-60F8B3C5AFCFQ34931052-A06AA929-2EB3-4330-86FD-673AB3323D1FQ35157045-6AB3D647-F81A-4EE2-B352-1A1C94ECFD97Q35681138-F23A151A-A6C5-46F7-BD86-09BFFC5630DDQ36041225-B3483F94-C5E1-4FDF-B6AC-09E150C78F2CQ36091912-833EDEE0-75C6-46AF-B097-F69910978296Q36161576-CF81CF55-F89F-4F1D-B996-23BEAB5E4059Q36399235-A5297EE4-659E-4AAE-A92A-65B98A0163AEQ36606116-EE14A0F1-76F0-4BB8-881F-00E8C4856DF2Q36649404-76897E96-0A9D-4F2B-A6E5-DDC34FF4E6D6Q36655827-229AF9ED-6F8A-4159-BEC9-A822DAEE0A74Q37087037-3B3E3579-A090-4298-825F-77A61694EFF3Q37620412-4B368CDD-23ED-4092-8C46-5FA1B0836C1DQ37642879-49F9736E-2D47-41AD-A578-22FB790DE821Q38290992-247EC7A7-6330-42CF-BBFA-BCC93B628137Q38306637-A0908E4D-903D-4891-A94E-62C944611F2CQ38483577-D79FB47E-9FC0-43BB-8490-78BD89E34602Q38500141-FFF2A2AC-47EE-4C67-B72B-97F5AC92275CQ38525874-4873ECAD-D785-4E05-81F7-6DA1F7A7E736Q38587375-020A59ED-06E9-4C1E-A88D-1A67E9B1E43AQ38680309-9266764C-3B43-4343-81B0-20C068016E04Q38720044-DC665ACB-D568-4148-82EB-E8BF41CF6392Q38787339-C1D4F023-6BC2-4697-9AF8-7DEBD4F5FF17Q38797090-FFEC447D-94F7-483A-A001-1A0BC0944ACCQ38815373-E90B1CBE-F3A8-4AF6-8275-12ED9C2D8171Q38837256-BC6387C5-C512-4139-AE0B-11C30DEDE98BQ38845301-4486DA2E-9185-480A-88ED-790CDBCF1074Q38959075-AD939CFB-7DD9-4D96-AA82-A72553536052Q38963273-29E12E64-EA40-422E-98A2-E69154EFED9AQ38966512-CAE89334-5E13-4ADF-9CBE-547BE2CEFDE8Q38988559-3976203F-6E41-4445-9D7A-C01DD8AD573CQ39025839-0C31384E-5341-4B55-AF83-D1C5C2A20E65Q39036848-BDEED03E-6155-4832-9214-4533CF4E1052Q39084627-4A5C7194-3B9B-4CF5-8E40-D3C6D6F7289C
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
IL-1 blockade in autoinflammatory syndromes.
@ast
IL-1 blockade in autoinflammatory syndromes.
@en
IL-1 blockade in autoinflammatory syndromes.
@nl
type
label
IL-1 blockade in autoinflammatory syndromes.
@ast
IL-1 blockade in autoinflammatory syndromes.
@en
IL-1 blockade in autoinflammatory syndromes.
@nl
prefLabel
IL-1 blockade in autoinflammatory syndromes.
@ast
IL-1 blockade in autoinflammatory syndromes.
@en
IL-1 blockade in autoinflammatory syndromes.
@nl
P2860
P1476
IL-1 blockade in autoinflammatory syndromes.
@en
P2093
Adriana A Jesus
Raphaela Goldbach-Mansky
P2860
P304
P356
10.1146/ANNUREV-MED-061512-150641
P577
2014-01-01T00:00:00Z